United Therapeutics (NASDAQ:UTHR) Shares Gap Down Following Insider Selling

Posted by on May 4th, 2023

Shares of United Therapeutics Co. (NASDAQ:UTHR – Get Rating) gapped down prior to trading on Wednesday after an insider sold shares in the company. The stock had previously closed at $228.79, but opened at $220.01. United Therapeutics shares last traded at $219.26, with a volume of 121,994 shares traded.

Specifically, EVP Paul A. Mahon sold 6,000 shares of United Therapeutics stock in a transaction dated Thursday, March 16th. The stock was sold at an average price of $214.39, for a total transaction of $1,286,340.00. Following the transaction, the executive vice president now directly owns 36,599 shares of the company’s stock, valued at approximately $7,846,459.61. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. In related news, CEO Martine A. Rothblatt sold 8,000 shares of the stock in a transaction that occurred on Wednesday, February 8th. The shares were sold at an average price of $253.38, for a total value of $2,027,040.00. Following the completion of the sale, the chief executive officer now directly owns 130 shares of the company’s stock, valued at approximately $32,939.40. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Paul A. Mahon sold 6,000 shares of the stock in a transaction that occurred on Thursday, March 16th. The stock was sold at an average price of $214.39, for a total transaction of $1,286,340.00. Following the completion of the sale, the executive vice president now directly owns 36,599 shares of the company’s stock, valued at $7,846,459.61. The disclosure for this sale can be found here. Over the last quarter, insiders sold 218,005 shares of company stock valued at $50,283,699. Company insiders own 12.40% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on the stock. Argus reduced their target price on shares of United Therapeutics from $300.00 to $280.00 and set a “buy” rating for the company in a report on Friday, April 21st. JPMorgan Chase & Co. increased their price objective on shares of United Therapeutics from $265.00 to $280.00 and gave the company an “overweight” rating in a report on Thursday, February 23rd. UBS Group cut their price objective on shares of United Therapeutics from $330.00 to $310.00 and set a “buy” rating for the company in a report on Monday, April 10th. LADENBURG THALM/SH SH cut their price objective on shares of United Therapeutics from $295.00 to $285.00 in a report on Thursday, February 23rd. Finally, Morgan Stanley cut their price objective on shares of United Therapeutics from $320.00 to $316.00 and set an “overweight” rating for the company in a report on Monday, April 10th. Two research analysts have rated the stock with a sell rating and nine have issued a buy rating to the company. Based on data from MarketBeat, United Therapeutics has a consensus rating of “Moderate Buy” and an average target price of $288.45.

United Therapeutics Stock Down 4.5 %

The company has a current ratio of 9.85, a quick ratio of 9.55 and a debt-to-equity ratio of 0.17. The stock has a market capitalization of $10.11 billion, a P/E ratio of 14.54 and a beta of 0.60. The business has a 50-day moving average price of $228.42 and a 200 day moving average price of $249.27.

United Therapeutics (NASDAQ:UTHR – Get Rating) last posted its earnings results on Wednesday, February 22nd. The biotechnology company reported $2.67 EPS for the quarter, missing analysts’ consensus estimates of $4.12 by ($1.45). The firm had revenue of $491.50 million for the quarter, compared to the consensus estimate of $519.20 million. United Therapeutics had a net margin of 37.56% and a return on equity of 16.30%. The firm’s revenue was up 18.4% compared to the same quarter last year. During the same quarter in the prior year, the company posted $2.35 earnings per share. On average, equities analysts expect that United Therapeutics Co. will post 17.91 EPS for the current fiscal year.

Institutional Trading of United Therapeutics

Institutional investors have recently bought and sold shares of the stock. Guardian Wealth Advisors LLC bought a new stake in United Therapeutics in the third quarter worth $27,000. Proficio Capital Partners LLC bought a new stake in United Therapeutics in the first quarter worth $29,000. Baldwin Brothers LLC MA bought a new stake in United Therapeutics in the fourth quarter worth $38,000. Machina Capital S.A.S. bought a new stake in United Therapeutics in the first quarter worth $45,000. Finally, Neo Ivy Capital Management bought a new stake in United Therapeutics in the second quarter worth $48,000. 95.63% of the stock is currently owned by institutional investors.

About United Therapeutics

(Get Rating)

United Therapeutics Corp. is a biotechnology company, which engages in the development and commercialization of products for patients with chronic and life-threatening conditions. Its products include Adcirca, Orenitram, Remodulin, TYVASO, and Unituxin. The company was founded by Martine A. Rothblatt on June 26, 1996 and is headquartered in Silver Spring, MD.

Featured Articles

Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.